Relf S J, Gharagozloo N Z, Skuta G L, Alward W L, Anderson D R, Brubaker R F
Department of Ophthalmology, Mayo Clinic and Foundation, Rochester, Minnesota 55905.
Am J Ophthalmol. 1988 Sep 15;106(3):251-5. doi: 10.1016/0002-9394(88)90356-x.
We performed a randomized double-masked evaluation of the alpha-adrenergic blocking agent thymoxamine (0.1%) as compared to placebo for the reversal of phenylephrine-induced mydriasis. Topically applied thymoxamine reversed the mydriasis from a single drop of 2.5% phenylephrine in 36 of 40 eyes (90%) within one hour. The mydriasis was completely reversed in 25 of 40 eyes (63%). Eyes with blue irides responded more quickly and more completely than did those with brown irides. The 40 contralateral eyes, which had also been dilated with phenylephrine, remained dilated or dilated further after receiving a placebo eyedrop. Twenty subjects (50%) reported mild transient ocular irritation upon instillation of thymoxamine. Thymoxamine was useful in individuals with narrow anterior chamber angles who were at risk of acute closed-angle glaucoma following dilation with an adrenergic agent.
我们进行了一项随机双盲评估,比较了α-肾上腺素能阻滞剂百里胺(0.1%)与安慰剂用于逆转去氧肾上腺素所致瞳孔散大的效果。局部应用百里胺可在1小时内使40只眼中的36只(90%)由一滴2.5%去氧肾上腺素所致的瞳孔散大得到逆转。40只眼中有25只(63%)的瞳孔散大被完全逆转。蓝色虹膜的眼睛比棕色虹膜的眼睛反应更快且更完全。另外40只对侧眼也用去氧肾上腺素进行了散瞳,在滴入安慰剂滴眼液后仍保持散大或进一步散大。20名受试者(50%)在滴入百里胺后报告有轻度短暂的眼部刺激。百里胺对前房角狭窄、在用肾上腺素能药物散瞳后有急性闭角型青光眼风险的个体有用。